Physician-ordered Genetic Testing for Cancer Patients: Improving Access and Equity through Mainstreaming

Bethan Powell, MD; Amie Blanco, MS, CGC; Kelly Gordon, MS, MLIS

**Evaluation Plan:**

* Assess overall reach and effectiveness of mainstreaming germline testing compared to GTS and traditional workflows using the following metrics:
* Percent of eligible patients for whom testing is ordered
* Percent of eligible patients who complete genetic testing
* Reasons for workflow attrition for those patients who do not complete testing
* Turnaround times from placement of order/referral to release of results
* Assess equitableness of mainstreaming workflow on an ongoing basis by evaluating metrics above across patient characteristics including race, ethnicity, age, gender, insurance, primary language, zip code, neighborhood deprivation index (NDI), and distance to care.
* Assess provider adoption of mainstream workflows by examining provider smartset ordering behavior compared to past and current referrals to genetics. Provider satisfaction will be assessed qualitatively by means of surveys. Data on number of providers that engage with the workflow will be evaluated on an ongoing basis in conjunction with each educational intervention (team meetings, videos, deployment of department champions). “Late adopters” will be surveyed to identify barriers to adoption. Where possible, barriers will be addressed.
* Assess ongoing uptake to promote maintenance of mainstreaming workflow.
	+ Assess the continued use of the traditional pre-test genetic counseling referral by specialty. Compare to referral rates for pre-test counseling prior to mainstreaming.
	+ Every three months after initial rollout, assess frequency of smartset orders compared to referrals for pre-test counseling for ovarian, breast, and advanced prostate cancer patients
	+ Identify providers who “revert” to traditional workflow and assess barriers or sources of dissatisfaction with mainstreaming workflow
* Assess impact of mainstreaming workflow on order volume of in-house CCGL germline genetic test.
	+ Examine trends in CCGL germline genetic test orders over time, including turn-around time.